Advancements in therapeutic targets and drug development for hyperuricemia: Mechanisms, progress, and challenges
- 1School of Pharmacy, Hangzhou Normal University, 2318 Yuhangtang Road, Hangzhou 311121, China
- 2Corresponding author.
Abstract
Hyperuricemia (HUA), characterized by elevated serum uric acid levels, is associated with various comorbidities such as gout, metabolic syndrome, cardiovascular diseases, renal disorders and diabetes, significantly compromising patients' quality of life. The global prevalence of hyperuricemia has increased, with a growing burden reported among younger populations, highlighting the need for effective management strategies. However, current urate-lowering therapies remain limited in variety and efficacy. Long-term urate-lowering therapy is indicated for symptomatic primary hyperuricemia (e.g., gout, tophi, or uric acid nephrolithiasis), whereas its use in asymptomatic cases remains controversial, with recommendations varying across guidelines, particularly for high-risk individuals. Even for patients who meet the treatment criteria, available drugs often prove inadequate, particularly in refractory cases, revealing a critical gap in safe and effective treatment options. To address this challenge, this review narratively outlines the key targets in urate-lowering therapy, including xanthine oxidase for uric acid production, the renal reabsorption transporter URAT1, and serum uric acid regulation, along with their underlying mechanisms. It also summarizes recent advances in urate-lowering agents and compares their pharmacokinetic and pharmacodynamic profiles. Beyond conventional pharmacological treatments, this review discusses emerging therapeutic strategies, including probiotic-based interventions, small interfering RNA -based therapies, and natural products. Furthermore, recent genetic studies and multi-omics analyses have identified potential therapeutic genes that merit further investigation and could inform the development of future treatments. By synthesizing findings from international research, this review aims to lay the groundwork for the development of innovative therapeutic approaches and advanced pharmacological strategies for hyperuricemia.
Related
- Advanced cell-laden hydrogels for diabetic wound healing: Biomaterial design, therapeutic mechanisms, and translational challenges
- Stimuli-Responsive Nanocarriers for Transdermal siRNA Delivery: Mechanisms, Challenges, and Therapeutic Strategies
- Artificial Intelligence in Pulmonary Hypertension: Advancements, Opportunities, and Challenges
- Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges
- Interactions between chronic kidney disease and hyperuricemia in children: mechanisms, clinical manifestations and management updates
BibTeX
@article{zhou2026advancements,
title = {{Advancements in therapeutic targets and drug development for hyperuricemia: Mechanisms, progress, and challenges}},
author = {Kexin Zhou and Lin Zhou and Zile Li and Jing Luo and Shuyue Song and Ruixin Wang and Xiabin Chen and Junsen Tong},
journal = {Experimental and Molecular Pathology},
year = {2026},
month = nov,
doi = {10.1016/j.yexmp.2026.105103},
url = {https://doi.org/10.1016/j.yexmp.2026.105103},
note = {CC BY},
}
RIS
TY - JOUR
TI - Advancements in therapeutic targets and drug development for hyperuricemia: Mechanisms, progress, and challenges
AU - Kexin Zhou
AU - Lin Zhou
AU - Zile Li
AU - Jing Luo
AU - Shuyue Song
AU - Ruixin Wang
AU - Xiabin Chen
AU - Junsen Tong
PY - 2026
DA - 2026/11/12
JO - Experimental and Molecular Pathology
DO - 10.1016/j.yexmp.2026.105103
UR - https://doi.org/10.1016/j.yexmp.2026.105103
AB - Hyperuricemia (HUA), characterized by elevated serum uric acid levels, is associated with various comorbidities such as gout, metabolic syndrome, cardiovascular diseases, renal disorders and diabetes, significantly compromising patients' quality of life. The global prevalence of hyperuricemia has increased, with a growing burden reported among younger populations, highlighting the need for effective management strategies. However, current urate-lowering therapies remain limited in variety and efficacy. Long-term urate-lowering therapy is indicated for symptomatic primary hyperuricemia (e.g., gout, tophi, or uric acid nephrolithiasis), whereas its use in asymptomatic cases remains controversial, with recommendations varying across guidelines, particularly for high-risk individuals. Even for patients who meet the treatment criteria, available drugs often prove inadequate, particularly in refractory cases, revealing a critical gap in safe and effective treatment options. To address this challenge, this review narratively outlines the key targets in urate-lowering therapy, including xanthine oxidase for uric acid production, the renal reabsorption transporter URAT1, and serum uric acid regulation, along with their underlying mechanisms. It also summarizes recent advances in urate-lowering agents and compares their pharmacokinetic and pharmacodynamic profiles. Beyond conventional pharmacological treatments, this review discusses emerging therapeutic strategies, including probiotic-based interventions, small interfering RNA -based therapies, and natural products. Furthermore, recent genetic studies and multi-omics analyses have identified potential therapeutic genes that merit further investigation and could inform the development of future treatments. By synthesizing findings from international research, this review aims to lay the groundwork for the development of innovative therapeutic approaches and advanced pharmacological strategies for hyperuricemia.
SN - 1096-0945
ER -